Loading…
GRI Bio, Inc. is projected to rise to $2.04 by 2027, a +17% move from its current price of $1.74. GRI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.67 | $1.74 | $1.81 | +0.01% |
| Jul 14 | $1.64 | $1.74 | $1.84 | +0.02% |
| Jul 15 | $1.62 | $1.74 | $1.87 | +0.02% |
| Jul 16 | $1.60 | $1.74 | $1.89 | +0.03% |
| Jul 17 | $1.59 | $1.74 | $1.91 | +0.04% |
| Jul 18 | $1.57 | $1.74 | $1.93 | +0.05% |
| Jul 19 | $1.56 | $1.74 | $1.94 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.56 | $1.74 | $1.94 | +0.05% |
| Week 2 | $1.49 | $1.74 | $2.03 | +0.11% |
| Week 3 | $1.44 | $1.74 | $2.10 | +0.16% |
| Week 4 | $1.40 | $1.74 | $2.17 | +0.21% |
| Week 5 | $1.37 | $1.74 | $2.22 | +0.27% |
| Week 6 | $1.34 | $1.75 | $2.28 | +0.32% |
| Week 7 | $1.31 | $1.75 | $2.33 | +0.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GRI Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapies targeting inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc.
and was founded in 2009. It is based in La Jolla, California.
GRI Bio, Inc. trades under the symbol GRI. The stock’s current price is $1.74 and its market capitalization is $3.08M, with a rank of 5370. The latest price context places the shares in a low-cap space with a narrow current price readout.
The forecast implies a flat-to-moderately rising path in the near term, with 2026 showing the most contained upside and longer horizons offering more substantial upside potential.
A major floor 22.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 33.3% above — a clean break opens room to run.
A major ceiling 69.0% above — clearing it would confirm fresh momentum.
Key GRI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GRI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.79 | Sell | $1.78 | Sell |
| MA 10 | $1.80 | Sell | $1.82 | Sell |
| MA 20 | $1.94 | Sell | $1.90 | Sell |
| MA 50 | $2.08 | Sell | $2.25 | Sell |
| MA 100 | $2.27 | Sell | $5.81 | Sell |
| MA 200 | $17.36 | Sell | $490.49 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.23 | Neutral |
| Stoch RSI (14) | 21.22 | Neutral |
| CCI (20) | -79.63 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -6.45 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.64 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 43.21 | Neutral |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 1.76 | Sell |
| ADX (14) | 18.76 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is bearish. The RSI(14) is 40, signaling modest downward pressure, while the 50-day simple moving average stands at $2.08 and the 200-day moving average at $17.36. Immediate support is at $1.74, with resistance at $2.32.
Over the last 30 days, the price has traded between $1.33 and $2.28, reflecting a tight but choppy range and elevated volatility at 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.74 | $1.74 | $2.35 | 0% | Neutral | |
| $1.55 | $2.04 | $2.88 | +17% | Neutral | |
| $1.95 | $2.68 | $4.00 | +54% | Bullish | |
| $1.73 | $2.47 | $3.82 | +42% | Bullish | |
| $1.59 | $2.35 | $3.77 | +35% | Bullish | |
| $1.48 | $2.26 | $3.72 | +30% | Bullish | |
| $1.34 | $2.10 | $3.55 | +21% | Bullish | |
| $1.74 | $2.80 | $4.86 | +61% | Bullish | |
| $1.90 | $3.16 | $5.59 | +81% | Bullish | |
| $1.75 | $2.97 | $5.36 | +71% | Bullish | |
| $2.15 | $4.11 | $8.05 | +136% | Bullish | |
| $2.37 | $5.27 | $11.58 | +203% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.74 | $1.74 | $2.20 | +0.00% |
| August 2026 | $1.52 | $1.82 | $2.26 | +4.67% |
| September 2026 | $1.45 | $1.75 | $2.21 | -3.80% |
| October 2026 | $1.49 | $1.81 | $2.31 | +3.50% |
| November 2026 | $1.53 | $1.88 | $2.43 | +3.86% |
| December 2026 | $1.45 | $1.80 | $2.35 | -4.51% |
Click any year to see its month-by-month GRI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GRI could reach as high as $2.35, with a base case around $1.74 and support toward $1.74 — roughly 0% from $1.74. A consolidation phase looks the most probable path here.
Expect GRI to range from $1.55 to $2.88 through 2027. The $2.04 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
The GRI price prediction for 2028 points to an average of $2.68 (low $1.95, high $4.00) — a potential gain of +54% on today's $1.74. Buyers look set to stay in control over this stretch.
In 2029, GRI is projected to trade between $1.73 and $3.82, averaging $2.47 — a potential gain of +42% from today's $1.74. That is -8% versus the projected 2028 average. Momentum favours further upside here.
GRI Bio, Inc.'s 2030 outlook centres on $2.35, within a $1.59 to $3.77 range. That is -5% versus the projected 2029 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, GRI could reach as high as $3.72, with a base case around $2.26 and support toward $1.48 — roughly +30% from $1.74. Momentum favours further upside here.
Expect GRI to range from $1.34 to $3.55 through 2032. The $2.10 average target implies a +21% move from current prices. That is -7% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The GRI price prediction for 2033 points to an average of $2.80 (low $1.74, high $4.86) — a potential gain of +61% on today's $1.74. Momentum favours further upside here.
In 2034, GRI is projected to trade between $1.90 and $5.59, averaging $3.16 — a potential gain of +81% from today's $1.74. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
GRI Bio, Inc.'s 2035 outlook centres on $2.97, within a $1.75 to $5.36 range. That is -6% versus the projected 2034 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2040, GRI could reach as high as $8.05, with a base case around $4.11 and support toward $2.15 — roughly +136% from $1.74. Buyers look set to stay in control over this stretch.
Expect GRI to range from $2.37 to $11.58 through 2050. The $5.27 average target implies a +203% move from current prices. That is up +28% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GRI today (≈ 574.712644 GRI) could be worth
$3,031.41
+$2,031.41 (+203%) by 2050 · US Dollar
Based on the average projected GRI price of $5.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GRIwould be worth at today's price.
$1,000 invested in GRI on Jul 10, 2025 (≈ 22.603977 GRI) would be worth
$39.33
-$960.67 (-96.1%) today · 0.04× · US Dollar
Based on a GRI entry price of $44.24 vs. today's $1.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.87 | $930.48 | -7.0% |
| 1 month ago | $2.31 | $753.25 | -24.7% |
| 3 months ago | $2.45 | $710.2 | -29.0% |
| 6 months ago | $6.78 | $256.79 | -74.3% |
| 1 year ago | $44.24 | $39.33 | -96.1% |
| All time (5.0y) ago | $6,978,207.5 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GRI forecast.
Our base-case forecast reaches $3.50 around 2040.
Implied market cap at $3.50: $6.2M
The multi-year forecast shows a path of gradual upside after a flat start in 2026. The 2026 forecast lists a min of $1.74, an avg of $1.74, a max of $2.35, with ROI of 0% and neutral sentiment. From 2027 onward, the outlook turns bullish with rising averages and higher ROIs: 2027 avg $2.04, max $2.88, ROI 17.1%; 2028 avg $2.68, max $4.00, ROI 54.3%; 2029 avg $2.47, max $3.82, ROI 41.8%; 2030 avg $2.35, max $3.77, ROI 35.2%.
The forecast continues to show upside through 2031–2032 and beyond, with 2033 avg $2.80 and max $4.86 (ROI 61.2%), 2034 avg $3.16 and max $5.59 (ROI 81.4%), and 2035 avg $2.97 and max $5.36 (ROI 70.9%). Longer horizons anticipate stronger moves, with 2040 avg $4.11 and max $8.05 (ROI 136.5%), and 2050 avg $5.27 and max $11.58 (ROI 203.1%). Overall, the trajectory is bullish in the outer years, with meaningful upside potential reflected in the higher annualized ROIs, albeit with year-to-year uncertainty intrinsic to such forecasts.
Tap a question to reveal the answer.
In 2030, the forecast shows min $1.59, avg $2.35, max $3.77 with ROI of 35.2% and sentiment BULLISH.
The forecast presents a mix: 2026 is NEUTRAL with ROI 0%, while later years are labeled BULLISH with growing averages and ROIs (for example, 2028 ROI 54.3%, 2034 ROI 81.4%, and 2050 ROI 203.1%). These figures are estimates and not guarantees.
The forecast shows a 2050 max of $11.58, which would imply a path to or beyond $10 in the longer term. Shorter horizons peak earlier, with 2040 max $8.05 and 2035 max $5.36.
The current price is $1.74 and the market cap is $3.08M.
For 2040, the min is $2.15, the average is $4.11, the max is $8.05, with ROI of 136.5% and a bullish sentiment.
GRI Bio, Inc. Community Discussion
0Share your GRI Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.